Clinical Scorecard: Intestinal Ultrasound Reveals Submucosal Hyper-Echogenicity Linked to Fat Accumulation and Predicts Lack of Response to Treatment in Ulcerative Colitis Patients

At a Glance

Key Highlights

• Submucosal hyper-echogenicity on intestinal ultrasound corresponds to fat deposition in the bowel wall of UC patients.
• Relative submucosal echogenicity (RSE) quantification predicts treatment response; higher RSE (>108 grayscale values) associates with non-response to anti-inflammatory therapy.
• Submucosal changes are more indicative of treatment outcomes than inflammation or collagen deposition alone.

Guideline-Based Recommendations

Diagnosis

• Use intestinal ultrasound (IUS) to assess bowel wall layers, focusing on submucosal thickness and echogenicity in UC patients.
• Quantify relative submucosal echogenicity (RSE) by comparing grayscale values of submucosa and muscularis propria to identify fat deposition.

Management

• Consider RSE values when evaluating likelihood of response to anti-inflammatory treatment in UC.
• Recognize that patients with high submucosal echogenicity may have persistent submucosal fat and may be less responsive to standard therapies.

Monitoring & Follow-up

• Perform follow-up IUS to monitor changes in submucosal echogenicity and bowel wall stratification during treatment.
• Use endoscopic Mayo score alongside IUS findings to assess treatment response.

Risks

• Persistent submucosal fat accumulation may indicate refractory disease and risk of non-response to anti-inflammatory agents.
• Loss of bowel wall stratification correlates with absence of submucosal fat and may reflect advanced disease.

Patient & Prescribing Data

Ulcerative colitis patients initiating anti-inflammatory treatment

Higher baseline RSE predicts lack of endoscopic response; RSE >108 grayscale values significantly reduces odds of treatment response.

Clinical Best Practices

• Incorporate intestinal ultrasound assessment of submucosal echogenicity into routine evaluation of UC patients.
• Use quantitative RSE measurements to stratify patients by likelihood of treatment response.
• Correlate IUS findings with histopathology when available to better understand transmural disease changes.
• Recognize that submucosal hyper-echogenicity reflects fat deposition rather than inflammation or fibrosis alone.
• Apply combined imaging and endoscopic scoring to guide personalized treatment decisions.

References

• Amsterdam UMC Study on Intestinal Ultrasound in UC
• Endoscopic Mayo Score and Treatment Response in UC